edrophonium has been researched along with ambenonium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Rashid, ZF; Beri, V; Cheung, J; Rosenberry, TL; Shiomi, K; Wildman, SA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for edrophonium and ambenonium
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for edrophonium and ambenonium
| Article | Year |
|---|---|
The natural product dihydrotanshinone I provides a prototype for uncharged inhibitors that bind specifically to the acetylcholinesterase peripheral site with nanomolar affinity.
Topics: Acetylcholine; Acetylcholinesterase; Aflatoxin B1; Binding Sites; Binding, Competitive; Catalysis; Catalytic Domain; Cholinesterase Inhibitors; Crystallography, X-Ray; Furans; Humans; Hydrolysis; Kinetics; Models, Chemical; Phenanthrenes; Pyrans; Quinones; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2013 |